Department of Medicine, Knapp Center for Biomedical Discovery, University of Chicago, Chicago, Illinois; Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan.
Department of Medicine, Knapp Center for Biomedical Discovery, University of Chicago, Chicago, Illinois; Division of Biology, Kansas State University, Manhattan, Kansas.
Cell Mol Gastroenterol Hepatol. 2021;11(2):491-502. doi: 10.1016/j.jcmgh.2020.08.008. Epub 2020 Aug 21.
BACKGROUND & AIMS: Inflammatory bowel diseases (IBD) are chronic inflammatory disorders where predictive biomarkers for the disease development and clinical course are sorely needed for development of prevention and early intervention strategies that can be implemented to improve clinical outcomes. Since gut microbiome alterations can reflect and/or contribute to impending host health changes, we examined whether gut microbiota metagenomic profiles would provide more robust measures for predicting disease outcomes in colitis-prone hosts.
Using the interleukin (IL) 10 gene-deficient (IL10 KO) murine model where early life dysbiosis from antibiotic (cefoperozone [CPZ]) treated dams vertically transferred to pups increases risk for colitis later in life, we investigated temporal metagenomic profiles in the gut microbiota of post-weaning offspring and determined their relationship to eventual clinical outcomes.
Compared to controls, offspring acquiring maternal CPZ-induced dysbiosis exhibited a restructuring of intestinal microbial membership in both bacteriome and mycobiome that was associated with alterations in specific functional subsystems. Furthermore, among IL10 KO offspring from CPZ-treated dams, several functional subsystems, particularly nitrogen metabolism, diverged between mice that developed spontaneous colitis (CPZ-colitis) versus those that did not (CPZ-no-colitis) at a time point prior to eventual clinical outcome.
Our findings provide support that functional metagenomic profiling of gut microbes has potential and promise meriting further study for development of tools to assess risk and manage human IBD.
炎症性肠病(IBD)是一种慢性炎症性疾病,迫切需要预测疾病发展和临床病程的生物标志物,以制定预防和早期干预策略,从而改善临床结局。由于肠道微生物组的改变可以反映和/或促成宿主健康的变化,我们研究了肠道微生物组宏基因组谱是否可以为易患结肠炎的宿主提供更有力的疾病结局预测指标。
我们使用白细胞介素(IL)10 基因缺陷(IL10 KO)的小鼠模型,其中来自接受抗生素(头孢哌酮[CPZ])处理的母鼠的早期生命失调通过垂直传递给幼崽,增加了幼崽以后患结肠炎的风险,我们研究了断奶后后代肠道微生物群的时间宏基因组谱,并确定了它们与最终临床结局的关系。
与对照组相比,从接受 CPZ 诱导的母体失调的后代中获得的后代表现出肠道微生物组成的改变,包括细菌组和真菌组的改变,这与特定功能子系统的改变有关。此外,在来自 CPZ 处理的母鼠的 IL10 KO 后代中,几个功能子系统,特别是氮代谢,在最终临床结局之前的时间点,在自发发生结肠炎(CPZ-结肠炎)的小鼠与未发生结肠炎(CPZ-无结肠炎)的小鼠之间出现了分歧。
我们的研究结果表明,肠道微生物的功能宏基因组分析具有潜力和前景,值得进一步研究,以开发评估风险和管理人类 IBD 的工具。